We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The US Supreme Court on Friday agreed to hear Novartis' appeal seeking to overturn a law that requires companies to wait 180 days after obtaining FDA approval for a biosimilar drug before they can begin marketing the product.